Cited 0 time in
Clinical utilization of cord blood over human health: Experience of stem cell transplantation and cell therapy using cord blood in Korea
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Lee, Young Ho | - |
| dc.date.accessioned | 2022-07-16T05:38:41Z | - |
| dc.date.available | 2022-07-16T05:38:41Z | - |
| dc.date.issued | 2014-03 | - |
| dc.identifier.issn | 1738-1061 | - |
| dc.identifier.issn | 2092-7258 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/160472 | - |
| dc.description.abstract | "Cord blood (CB) has been used as an important and ethical source for hematopoietic stem cell transplantation (SCT) as well as cell therapy by manufacturing mesenchymal stem cell, induced pleuripotenti al stem cell or just isolating mononuclear cell from CB. Recently, the application of cell-based therapy using CB has expanded its clinical utility, particularly, by using autologous CB in children with refractory diseases. For these purposes, CB has been stored worldwide since mid-1990. In this review, I would like to briefly present the historical development of clinical uses of CB in the fields of SCT and cell therapy, particularly to review the experiences in Korea. Furthermore, I would touch the recent banking status of CB. | - |
| dc.format.extent | 7 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | 대한소아청소년과학회 | - |
| dc.title | Clinical utilization of cord blood over human health: Experience of stem cell transplantation and cell therapy using cord blood in Korea | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.3345/kjp.2014.57.3.110 | - |
| dc.identifier.scopusid | 2-s2.0-84896474338 | - |
| dc.identifier.bibliographicCitation | Clinical and Experimental Pediatrics, v.57, no.3, pp 110 - 116 | - |
| dc.citation.title | Clinical and Experimental Pediatrics | - |
| dc.citation.volume | 57 | - |
| dc.citation.number | 3 | - |
| dc.citation.startPage | 110 | - |
| dc.citation.endPage | 116 | - |
| dc.type.docType | Review | - |
| dc.identifier.kciid | ART001859068 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.subject.keywordPlus | C peptide | - |
| dc.subject.keywordPlus | CD45 antigen | - |
| dc.subject.keywordPlus | thymocyte antibody | - |
| dc.subject.keywordPlus | acute graft versus host disease | - |
| dc.subject.keywordPlus | acute granulocytic leukemia | - |
| dc.subject.keywordPlus | acute lymphoblastic leukemia | - |
| dc.subject.keywordPlus | aplastic anemia | - |
| dc.subject.keywordPlus | bone marrow transplantation | - |
| dc.subject.keywordPlus | CD34 selection | - |
| dc.subject.keywordPlus | cell therapy | - |
| dc.subject.keywordPlus | cognitive defect | - |
| dc.subject.keywordPlus | engraftment syndrome | - |
| dc.subject.keywordPlus | event free survival | - |
| dc.subject.keywordPlus | graft failure | - |
| dc.subject.keywordPlus | hematopoietic stem cell transplantation | - |
| dc.subject.keywordPlus | human | - |
| dc.subject.keywordPlus | Korea | - |
| dc.subject.keywordPlus | motor dysfunction | - |
| dc.subject.keywordPlus | overall survival | - |
| dc.subject.keywordPlus | review | - |
| dc.subject.keywordPlus | tissue regeneration | - |
| dc.subject.keywordPlus | tumor microenvironment | - |
| dc.subject.keywordPlus | umbilical cord blood | - |
| dc.subject.keywordAuthor | Cell therapy | - |
| dc.subject.keywordAuthor | Cord blood | - |
| dc.subject.keywordAuthor | Transplantation | - |
| dc.identifier.url | https://www.e-cep.org/journal/view.php?doi=10.3345/kjp.2014.57.3.110 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
